Pfeffer MA, et al.. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247–2257.

• Crossref
Pfeffer MA, . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247–2257.10.1056/NEJMoa1509225)| false
• Search Google Scholar
• Export Citation

Mann JFE, et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839–848.

• Crossref
Mann JFE, . Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839–848.10.1056/NEJMoa1616011)| false
• Search Google Scholar
• Export Citation

Marso SP, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–322.

• Crossref
Marso SP, . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–322.10.1056/NEJMoa1603827)| false
• Search Google Scholar
• Export Citation

Tuttle KR, et al.. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605–617.

• Crossref
Tuttle KR, . Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605–617.10.1016/S2213-8587(18)30104-9)| false
• Search Google Scholar
• Export Citation

Marso SP, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834–1844.

• Crossref
Marso SP, . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834–1844.10.1056/NEJMoa1607141)| false
• Search Google Scholar
• Export Citation

American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2019. Diabetes Care 2019; 42:S90–S102.

American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2019. Diabetes Care 2019; 42:S90–S102.)| false
• Search Google Scholar
• Export Citation

Tuttle KR, et al.. CKD outcomes in type 2 diabetes and moderate-to-severe CKD treated with dulaglutide versus insulin glargine: AWARD-7 [Poster]. JASN Kidney Week Edition Abstract Supplement 2018. 2018; Poster TH-OR033.

Tuttle KR, . CKD outcomes in type 2 diabetes and moderate-to-severe CKD treated with dulaglutide versus insulin glargine: AWARD-7 [Poster]. JASN Kidney Week Edition Abstract Supplement 2018. 2018; Poster TH-OR033.)| false
• Search Google Scholar
• Export Citation

Mann JFE, et al.. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation 2018; 138:2908–2918.

• Crossref
Mann JFE, . Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation 2018; 138:2908–2918.10.1161/CIRCULATIONAHA.118.036418)| false
• Search Google Scholar
• Export Citation

Sun F, et al.. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110:26–37.

• Crossref
Sun F, . Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110:26–37.10.1016/j.diabres.2015.07.015)| false
• Search Google Scholar
• Export Citation

Potts JE, et al.. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10:e0126769.

• Crossref
Potts JE, . The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10:e0126769.10.1371/journal.pone.0126769)| false
• Search Google Scholar
• Export Citation

Vilsboll T, et al.. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.

• Crossref
Vilsboll T, . Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.10.1136/bmj.d7771)| false
• Search Google Scholar
• Export Citation

Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol 2018; 315:F1519–F1525.

• Crossref
Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol 2018; 315:F1519–F1525.10.1152/ajprenal.00211.2018)| false
• Search Google Scholar
• Export Citation

Tanaka T, et al.. The potential for renoprotection with incretin-based drugs. Kidney Int 2014; 86:701–711.

• Crossref
Tanaka T, . The potential for renoprotection with incretin-based drugs. Kidney Int 2014; 86:701–711.10.1038/ki.2014.236)| false
• Search Google Scholar
• Export Citation